Vivek Subbiah: How does PARP Inhibitor affect BARD1-Mutated Neuroblastoma?

Vivek Subbiah shared on LinkedIn:

“BARD1 = encodes the BRCA1-associated RING domain 1 protein which forms the BRCA1-BARD1 heterodimer to repair DNA double-strand breaks by homologous recombination.

Interesting report published in NEJM.

Clinical Response to a PARP Inhibitor and Chemotherapy in a Child with BARD1-Mutated Refractory Neuroblastoma-

• Loss of BARD1 has been shown to confer homologous recombination repair (HRR) deficiency in adult cancer cell lines.
• FDA approved olaparib, a PARPi, for treating metastatic castration-resistant prostate cancer harboring mutations in HRR genes including BARD1.

‘Response to PARP Inhibition in BARD1-Mutated Refractory Neuroblastoma‘”

Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.